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 Abstract 
 Respiratory syncytial virus (RSV) presents very similar 
to influenza and is the principle cause of bronchi-
olitis in infants and young children worldwide. Yet, 
there is no systematic monitoring of RSV activity in 
Australia. This study uses existing published data 
sources to estimate incidence, hospitalisation rates, 
and associated costs of RSV among young children 
in Australia. Published reports from the Laboratory 
Virology and Serology Reporting Scheme, a passive 
voluntary surveillance system, and the National 
Hospital Morbidity Dataset were used to estimate 
RSV-related age-specific hospitalisation rates in 
New South Wales and Australia. These estimates 
and national USA estimates of RSV-related hospital-
isation rates were applied to Australian population 
data to estimate RSV incidence in Australia. Direct 
economic burden was estimated by applying cost 
estimates used to derive economic cost associated 
with the influenza virus. The estimated RSV-related 
hospitalisation rates ranged from 2.2–4.5 per 
1,000 among children less than 5 years of age 
to 8.7–17.4 per 1,000 among infants. Incidence 
ranged from 110.0–226.5 per 1,000 among the 
under five age group to 435.0–869.0 per 1,000 
among infants. The total annual direct healthcare 
cost was estimated to be between $24 million and 
$50 million. Comparison with the health burdens 
attributed to the influenza virus and rotavirus sug-
gests that the disease burden caused by RSV is 
potentially much higher. The limitations associated 
with using a passive surveillance system to estimate 
disease burden, and the need to explore further 
assessments and to monitor RSV activity are dis-
cussed.  Commun Dis Intell 2011;35(2):177–184.
 Keywords: respiratory syncytial virus, respiratory 
tract infections, burden of disease, Australia
 Introduction
 The Influenza A H1N1 pandemic of 2009 served 
as a reminder of the importance of monitoring in 
the detection and management of infectious dis-
ease outbreaks. In Australia, laboratory confirmed 
influenza is by law, a notifiable disease that needs 
to be reported to the National Notifiable Diseases 
Surveillance System and is thereby reported rou-
tinely. There is however little recognition of the role 
that the respiratory syncytial virus (RSV) plays in the 
burden of disease that is attributed to the influenza 
virus the world over.
 With a disease spectrum ranging from rhinitis and 
otitis media to bronchiolitis and pneumonia, RSV 
infection presents very similar to influenza and con-
tributes to the influenza-like illness that occurs in 
the community. 1–2  It is the principal cause of bron-
chiolitis in infants and young children worldwide, 
with incidence peaking between 2 and 5 months of 
age and almost all children being exposed to RSV by 
the time they reach 3 years of age. 3 
 Overseas studies suggest a high disease burden in 
industrial nations. In the United Kingdom, it is 
estimated that among the under 5 years age group, 
general practitioner consultation rates due to RSV 
are similar to that of influenza, while RSV accounts 
for more hospital admissions than does influenza 
(35,540 and 9,967 respectively), particularly among 
pre-school aged children. 4  In the year 2000 in the 
United States of America (USA), RSV-related hos-
pital admissions accounted for 17% of all hospitali-
sation of infants aged 3–12 months. 5  In Japan, it is 
estimated that a quarter (26.2%) of children aged less 
than 3 years of age are treated annually for RSV and 
13.6% are hospitalised. 6  The medical cost associated 
with RSV in children less than 5 years of age in the 
USA in 2000 was estimated to be $US652 million; 
60% of this cost attributed to hospitalisations. 5 
 In Australia, while a small number of studies have 
examined viral cultures taken in hospital to help cre-
ate a picture of RSV burden, there is no systematic 
collection of data on RSV to estimate the health 
and economic burden specific to Australia. This 
study draws on published data to derive an estimate 
of RSV occurrence in Australia and compares the 
disease burden with that caused by other highly 
prevalent viruses.
 Methods
 RSV is not a notifiable disease in Australia and there 
is no single data source that accurately measures 
RSV activity across Australia. The primary data 
source for this study is the Laboratory Virology 
and Serology Reporting Scheme (LabVISE), a 
passive surveillance system involving a network of 
17–20 laboratories across Australia voluntarily sub-
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mitting monthly reports on the laboratory identifi-
cation of viruses and other organisms. 7  Specifically, 
two studies that have examined RSV reporting in 
LabVISE have been used to estimate the number of 
cases of RSV-related hospitalisations and hospitali-
sation rates that occur in Australia. 8–9 
 The first of the two LabVISE based studies was pub-
lished in 2000 and presents the number of RSV cases 
in New South Wales reported to LabVISE during 
the period January 1993 and December 1997. 8  The 
authors, in presenting the number of RSV cases 
reported to LabVISE, identify that these numbers 
are ‘likely to represent hospitalised cases (and that 
the data) reflect a pattern of hospitalisation rather 
than RSV infection in the community.’ 8  Given 
the absence of more comprehensive data sources, 
and recognising the limitations of using a passive 
surveillance system to estimate the occurrence of 
disease, the number reported to LabVISE is used in 
this study as a surrogate indicator of the number of 
RSV hospitalisations in New South Wales.
 The second study published in 2002 reviewed 
Australia-wide reporting of RSV as part of viral 
and non-viral pathogen identifications reported to 
LabVISE during the 10 year period 1991–2000. 9  As 
with the RSV reporting for New South Wales, the 
number of RSV cases reported across Australia is 
used in this study as a surrogate indicator for RSV 
hospitalisations in Australia. This study does not 
provide an age breakdown of RSV occurrence in 
Australia. Being uncertain about how the New 
South Wales age distribution of RSV compares with 
that of Australia, and in view of the fact that the age 
distribution of the Australian and the USA popula-
tions and the New South Wales and the Australian 
populations are similar, 10  the age distribution of 
RSV from a national estimate for the USA 5  was 
applied to the number of RSV cases reported in 
Australia to estimate RSV hospitalisation rates in 
Australia (Table 1).
 The number of RSV hospitalised cases obtained from 
the two studies (Table 1) were then applied to the New 
South Wales and Australian population distributions 
of 1996 and 2000 to derive RSV hospitalisation rates 
for New South Wales and Australia (Table 1).
 A second data source used in this study to inform the 
number of RSV-related hospitalisations in Australia 
is the National Hospital Morbidity Database 
(NHMD) as reported by the Australian Institute 
of Health and Welfare (AIHW). 11  The number 
of hospital separations registered from all states 
and territories in Australia in the NHMD with a 
discharge diagnosis of ICD-10-AM codes B97.4 
(RSV), J12.1 (RSV pneumonia), J20.5 (acute RSV 
bronchitis), or J21.0 (acute RSV bronchiolitis) for 
the year 1999–2000 was obtained via the data cubes 
published on the AIHW website. 12  Table 2 presents 
and compares the NHMD derived estimates of hos-
pitalisation rates with those presented in Table 1 and 
with national USA estimates.
 To estimate the incidence of RSV in Australia, the 
proportion of RSV cases expected to be hospitalised 
was applied to the hospitalisation rates presented 
in Table 2. Given the absence of a definite estimate 
of the proportion of RSV cases that require hospi-
talisation, the upper end of the published statistics 
that 0.5%– 2% of all cases with RSV in the infant 
age group require hospitalisation 3  was used as the 
proportion. The upper end was used as this would 
provide a lower estimate of incidence, thereby 
reducing the likelihood of over-estimating RSV 
occurrence. Since RSV hospitalisation rates derived 
from NHMD were higher than the LabVISE esti-
mates (Table 2) and given the fact that NHMD is an 
actual count of the number of RSV-related hospital 
separations as opposed to an estimation based on 
a passive surveillance system, the NHMD derived 
hospitalisation rates have been used separately to 
estimate RSV incidence in Australia. The LabVISE 
estimated hospitalisation rates and the USA national 
estimate have been combined as a range.
 The estimated incidence and hospitalisation rates 
are used to calculate an economic burden of RSV in 
Australia. In the absence of data to inform the eco-
nomic costing, the cost estimation is limited to the 
direct health care costs associated with hospitalisation. 
The average cost of a RSV-related hospital admis-
sion was taken to be $5,245, which is the Australian 
Refined Diagnosis Related Groups based average cost 
of a hospital admission for influenza or pneumonia 
over the period 1998–2005 (in 2005 dollar value) 
used to estimate the economic cost of influenza to the 
Australian health system. 13  Applying the value used 
to estimate the cost of influenza is justifiable on the 
basis that influenza and RSV are very similar in terms 
of clinical presentation and have comparable lengths 
of stay in hospital (median of 2–4 days for RSV 5,14  and 
2 days for influenza 15 ). In estimating the total direct 
healthcare costs associated with RSV infections, it is 
assumed, based on existing literature, 5  that 60% of 
direct costs are incurred in hospital.
 To place these estimates in perspective, the RSV-
related burden of disease estimated in this study 
was compared against published hospitalisation 
rates for influenza in Sydney, New South Wales, for 
the period 1994–2001. 16  Given that the influenza 
vaccine was introduced in Australia as part of the 
mass immunisation program in 1999, the period 
1994–2001 mostly represents pre-vaccination period 
for influenza virus and is therefore comparable to 
the current RSV situation of no vaccination. Also 
used as a comparator was the number of reports of 
influenza to LabVISE from 1991–2000. 9  Once again, 
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this largely constitutes the pre-immunisation period 
for influenza and is therefore a suitable comparison.
 Just as RSV is now recognised to be a major contributor 
to lower respiratory tract infections in infants and young 
children, rotavirus is the major cause of gastroenteritis 
among infants and young children in Australia. In 
common with RSV, rotavirus transmission in temper-
ate climates is seasonal, occurring predominantly 
during the winter season. Estimated RSV-related hos-
pitalisation rates are compared with published reports 
on rotavirus-related hospitalisation rates and disease 
burden for the period 1991–2002. 11,17  Rotavirus immu-
nisation was not added to the Australian National 
Immunisation Program until 2007.
 Results
 In New South Wales a total of 4,665 cases of RSV 
was reported to LabVISE between January 1993 and 
December 1997, with the number of cases per year 
ranging from 770–1,131. 8  Across Australia, RSV was 
the single most common virus reported to LabVISE 
during the 10 year period 1991–2000 with a total of 
36,346 cases reported, and the annual number of 
cases ranging from 2,555 to 4,641. 9  Consistent with 
published literature and similar to influenza, 18–19  
annual epidemics occurred in winter and the major-
ity of cases of RSV reporting was for children less 
than 5 years of age. 9 
 The hospitalisation rates estimated based on the 
number of cases reported to LabVISE, suggest that 
while the rates for New South Wales were margin-
ally lower than rates based on the 10-year review of 
Australia-wide reporting of RSV, the estimates for 
New South Wales and Australia were not dissimilar 
(Table 1). The difference, if at all, was more among 
the young infant age group.
 Table 2 compares the estimates from the two 
LabVISE studies with hospitalisation rates derived 
from the NHMD and the national USA estimates. 
The NHMD rates are higher than rates estimated 
from the LabVISE-based studies and are more in 
keeping with the USA national estimate reported by 
Paramore et al 5  (Table 2). As a result, the NHMD 
derived hospitalisation rates were used separately for 
estimating the RSV incidence for Australia.
 Applying the hospitalisation rates derived in Table 2 
to the 2006 Australian Census population estimates 
that up to 5,710 RSV-related hospital episodes may 
occur every year among children less than 5 years of 
age in Australia (Table 3). Assuming the upper limit 
from the published literature that up to 2% of RSV 
cases are hospitalised, 3  this converts to up to 285,481 
cases of RSV occurring in Australia among children 
aged less than 5 years; with the majority of these 
cases occurring among the less than 1 year age group 
(Table 3). There wasn’t sufficient data to examine 
in detail the distribution within the less than 1 year 
age group as would have been ideal given that the 
literature suggest a high disease burden observed in 
the less than 3 month age group.
 Applying the average cost of $5,245 per hospital 
admission, the 2,773 to 5,710 hospital episodes esti-
mated per year for the < 5 year age group (Table 3) 
will cost the Australian health system between 
$14.544 m and $29.949 m per year in hospital costs 
(Table 4). If, as suggested by USA and Canadian 
literature, hospital costs account for around 60% of 
the total direct health care costs of RSV infections in 
young children, the cost of RSV on the Australian 
health system is estimated to be between $24 and 
$50 million annually (in 2005 value). No informa-
tion is available to estimate non-health care or indi-
rect costs attributable to RSV.
 Table 2:  Age-specific respiratory syncytial virus (RSV) related-hospitalisation rates per 1,000 
population for Australia and the United States of America (USA) as estimated by various sources 
LabVISE*
(1993–1997)
NSW
LabVISE
(1991–2000)
Australia
NHMD†
(1999/2000)
Australia
Paramore
(2001)
USA (national estimate)
RSV hospitalisations (n) 770–1,131 per year‡ 2,555–4,640 per year§ 5,244 87,105 annually
Hospitalisation rate by age group (per 1,000 population)
All ages 0.1–0.2|| 0.1–0.3|| – –
< 1 year 8.7|| 10.6|| 16.8 17.4
< 5 years 2.2|| 2.8|| 3.9 4.5
 
 * Laboratory Virology and Serology Reporting Scheme.
 † National Hospital Morbidity Dataset.
 ‡ Number of cases in New South Wales as reported in Lister et al, 2000. 8
 § Number of cases across Australia as reported in Roche et al, 2002. 9 
 || From Table 1. 
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 Comparing the estimated RSV-related disease bur-
den with those attributed to the influenza virus and 
rotavirus suggest that in Australia amongst children, 
RSV is responsible for a much higher disease burden 
than the routinely monitored influenza virus and 
rotavirus (Figure). A Sydney-based study reports 
influenza-related hospitalisation rates varying from 
0.95–6.94 per 1,000 population among children 
aged less than 1year (the group with the highest rate 
of hospitalisation), 16  whereas this study’s estimates 
of RSV-related hospitalisation rates for the less than 
1 year age group were almost 10 times higher (8.7 and 
16.8 per 1,000 age-specific population) (Tables 1 
and 2). The annual number of cases reported to 
LabVISE is also lower for influenza with approxi-
mately 200–1,000 cases per month of influenza A 
and 10–300 cases per month of influenza B reported 
during peak influenza season. 9  This is in contrast 
to about 1,000 cases of RSV reported per month as 
the usual number, with up to about 1,600 cases a 
month reported in one year. 9  A total of 13,191 cases 
of influenza A and 3,614 cases of influenza B cases 
was reported to LabVISE over the 10-year period 
(from 1991 to 2000), whereas a total of 36,346 cases 
of RSV was reported to LabVISE during the same 
10 year period. 9  Hospitalisation rates in Australia 
for rotavirus among children less than 5 years of age 
have been estimated previously to be between 3.0 per 
1,000 (for 1–4 year age group) and 4.1 per 1,000 (for 
the less than 1 year age group), 11  which once again is 
less than the 2.2–4.5 per 1,000 that was estimated for 
this same age group for RSV (Table 2).
 Discussion
 Our analysis based, on limited available data on RSV 
in Australia, suggests that RSV potentially causes a 
higher disease burden compared with viruses such 
as influenza or rotavirus that are monitored through 
surveillance programs and are vaccinated against 
as part of the national immunisation program in 
Australia. The lack of systematic monitoring sys-
tems in Australia for RSV meant that this study was 
limited to using data from published sources. This 
meant that the data are not the most recent and are 
subject to systematic errors when used to estimate 
the burden of disease for Australia.
 The limitations of using a passive surveillance system 
as the primary source of data are recognised, and it 
 Table 4:  Estimated cost of hospitalisation and direct health care cost for respiratory syncytial 
virus infections, Australia, (2005 value) 
Age group < 1 year < 5 years
Estimated number of RSV hospitalisations (annual) 2,263–4,521* 2,773–5,710*
Direct cost of hospitalisation per year ($ million)† $11.869–$23.713 $14.544–$29.949
Total direct health care cost per year ($ million)‡ $19.782–$39.521 $24.241–$49.915
 
 * From Table 3.
 † Unit cost = average cost of infl uenza/pneumonia as estimated by Newall et al = $5,245. 13 
 ‡ Total healthcare costs estimated based on reports that hospitalisation costs in respiratory syncytial virus (RSV) account for 
60% of all direct health care costs associated with RSV. 5 
 Table 3:  Estimated incidence of respiratory syncytial virus infections, Australia, based on 
hospitalisation rates 
Age group
Hospitalisation rate per 
1,000 population
(A)
Age-specifi c 
Population†
(B)
Expected 
number of 
hospitalisations
(C) = (A)x(B)
Number of RSV 
cases /year ‡
(D)=(C) x 50
Incidence 
per 1,000 
population§
[(D) / (B)] x 
1,000
< 1 year 16.8 (Table 2 NHMD)* 260,101 4,362 218,095 838.5
< 1 year 8.7–17.4 (Table 2 range) 260,101 2,263–4,521 113,144–226,028 435.0–869.0
< 5 years 3.9 (Table 2 NHMD)* 1,260,403 4,916 245,779 195.0
< 5 years 2.2–4.5 (Table 2) 1,260,403 2,773–5,710 138,644–285,481 110.0–226.5
 
 * National Hospital Morbidity Dataset (NHMD) derived hospitalisation rates have been applied separately as these rates were 
higher than the Laboratory Virology and Serology Reporting Scheme–derived rate estimates for Australia (Table 2).
 †    Australian Bureau of Statistics Census 2006 accessed via the Australian Bureau of Statistics web site, Census data, 2006 
Census (Australia, quick statistics).
 ‡ Assumes that hospitalisation = 2% of incidence. 3 
 § Per 1,000 age-specifi c population (Australia). 
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is acknowledged that such surveillance systems only 
provide a means of examining overall trends. 9  The 
implication of LabVISE being a passive surveillance 
system on this study is that the derived estimates 
underestimate the true disease burden. This fact 
is supported to some extent by the finding that the 
LabVISE estimated RSV hospitalisation rates were 
less than the NHMD derived rates (Table 2). The 
use of LabVISE to estimate hospitalisation has been 
considered previously by Roche and colleagues who 
state that the ‘number of LabVISE reports of RSV 
was of the same order as total admissions for bron-
chiolitis.’ 20  They go on to say that ‘It is likely (that) 
LabVISE captures the majority of hospitalised cases 
of RSV through its networks or tertiary hospital 
laboratories in major Australian cities.’ 20  For the 
purpose of this study, it is believed that LabVISE 
and the use of NHMD jointly provide information 
to demonstrate the high disease burden caused by 
RSV, particularly in relation to the influenza viruses 
and rotavirus.
 Another limitation is the absence of a recent and 
definite estimate of the proportion of RSV cases that 
require hospitalisation, and the consequent use of 
statistics from a text book quoted in a journal paper. 
The implication of using the 2% upper end of the 
quoted range is that the incidence would be lower 
than had the 0.5% lower end of the range been used. 
The 0.5%–2% hospitalisation rate also relates to 
infants, and since infancy is a significant risk factor 
for hospitalisation, 21  it is reasonable to assume that 
the hospitalisation rates across all ages would be 
lower. The decreasing hospitalisation rate with age 
was also demonstrated in a conference paper pre-
sented by the Centre for Disease Control personnel 
in 2010 presenting national estimates of RSV-related 
hospitalisations for the period 1997 to 2006 for the 
USA. The estimates presented for the less than 
1 age group were 2.63% in 1997–1999 and 2.34% in 
2004–2006. The rates reduced with age, from 1.19% 
in the 1 to less than 2 year age group, to 0.19% in the 
2 to less than 5 year age group. 22 
 Counter arguments may also exist to explain higher 
rates of RSV being reported when in fact RSV 
infection rates are no more than the occurrence of 
influenza or rotavirus. For example, it may be pos-
sible that the diagnosis of influenza or rotavirus is 
often made based on clinical judgement not requir-
ing serological assay, while testing for RSV may be 
undertaken more frequently. This may result in a 
higher number of RSV reportings that do not neces-
sarily reflect the true disease burden.
 Notwithstanding these limitations and possible 
explanations, the finding in this study that RSV is 
possibly contributing to a significant disease burden 
in Australia, especially when compared with influ-
enza and rotavirus that are considered sufficiently 
significant to warrant monitoring and vaccination, 
needs further investigation. If RSV is a significant 
contributor to influenza-like illness and the associ-
ated economic burden, there is a need to accurately 
assess and understand the burden and to identify 
goals and strategies to protect and reduce morbidity, 
especially among high-risk groups.
 The benefits of preventing RSV extend beyond 
reducing morbidity and mortality directly related 
to RSV among the high-risk groups. In common 
with other respiratory tract viral pathogens, RSV is 
associated with exacerbation of asthma. 23  While the 
majority of infants and young children infected with 
RSV experience a full recovery, there is evidence 
to suggest an association between RSV infection 
in early childhood and the likelihood of wheez-
ing, or developing asthma. 3,24–27  This association is 
of particular relevance for Australia given that the 
prevalence of asthma in Australia is among the 
highest in the world, affecting 14%–16% children 
and 10%–12% adults. 28 
 To date, no vaccine has been proved to be safe 
and effective in the control of RSV, and treatment 
is largely symptomatic. Prophylactic monoclonal 
antibody therapy has been shown to be effective 
in reducing the morbidity associated with RSV, 
however given the significant cost of the interven-
tion, the current recommendation by the National 
Health amd Medical Research Council is to limit its 
use to high risk groups. 29
 Figure:  Disease burden caused by influenza A 
and B, rotavirus, and respiratory syncytial 
virus in Australia 
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 Given that this study suggests a disease burden 
higher than those attributed to the influenza viruses 
or rotavirus prior to the introduction of vaccines, 
there is a need to further assess the disease burden 
and explore the value of monitoring RSV activity in 
Australia, primarily to establish a baseline level of 
activity, but also to assist in prioritising, implement-
ing, and assessing control measures that may be 
required.
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